All publications

Export 26 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Adult  [Clear All Filters]
2014
Hué S, Brown A.E, Ragonnet-Cronin M, Lycett SJ, Dunn D, Fearnhill E, Dolling D, Pozniak A, Pillay D, Delpech V et al..  2014.  Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS. 28:1967-75.
Hodcroft EB, Hadfield J, Fearnhill E, Phillips A, Dunn D, O’Shea S, Pillay D, Leigh Brown A.J.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn D, Bibby D., Hill T, Sabin C, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
2013
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips A, Dunn D.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Santoro MM, Sabin C, Forbici F., Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Dolling D, Dunn D, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin C, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Mackie NE, Dunn D, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin C, Geretti A M.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
De Luca A., Dunn D, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
2012
Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A.J, Churchill D, Williams I, Geretti A M et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn D.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
2011
Wittkop L., Gunthard H.F, de Wolf F., Dunn D, Cozzi-Lepri A, De Luca A., Kucherer C., Obel N., von Wyl V., Masquelier B. et al..  2011.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.
Bansi L, Smith C, Phillips A, Kirk S., Geretti A M, Johnson M, Mackie NE, Post FA, Gazzard B, Dunn D et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Prosperi M.C, Mackie NE, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
2010
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S.  2010.  Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC).  2010.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.
Mackie NE, Phillips A, Kaye S, Booth C, Geretti A M.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Harrison LJ, Castro H, Cane P A, Pillay D, Booth C, Phillips A, Geretti A M, Dunn D.  2010.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.
Bansi L, Geretti A M, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn D.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.
2009
Geretti A M, Harrison LJ, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.